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Insulin signalling deﬁciencies and insulin resistance have been directly linked to the progression of neurodegenerative disorders like
Alzheimer’s disease. However, to date little is known about the underlying molecular mechanisms or insulin state and distribution
in the brain under pathological conditions. Here, we report that insulin is accumulated and retained as oligomers in hyperpho-
sphorylated tau-bearing neurons in Alzheimer’s disease and in several of the most prevalent human tauopathies. The intraneuronal
accumulation of insulin is directly dependent on tau hyperphosphorylation, and follows the tauopathy progression. Furthermore,
cells accumulating insulin show signs of insulin resistance and decreased insulin receptor levels. These results suggest that insulin
retention in hyperphosphorylated tau-bearing neurons is a causative factor for the insulin resistance observed in tauopathies, and
describe a novel neuropathological concept with important therapeutic implications.
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Introduction
Although the brain was previously considered an insulin-
insensitive organ, insulin is now well known to cross the
blood–brain barrier through a receptor-mediated saturable
transport. The main source of insulin in the brain is per-
ipheral, but some research groups have reported endogen-
ous insulin synthesis in hippocampal neurons and to a less
extent in neurons of the cerebral neocortex (Molna´r et al.,
2014), Purkinje cells of the cerebellar cortex and the gran-
ule cell layer of the olfactory bulb (Devaskar et al., 1994).
The relevance of insulin in the regulation of glucose uptake
and metabolism in the brain has been subject of some con-
troversy, however, very recent reports have shown that
knockout (KO) mice for the insulin receptor in astrocytes
present decreased glucose transporter-1 (GLUT1) levels,
and an overall decrease in glucose consumption in the
brain, which suggest that insulin pays a key role in the
maintenance of glucose homeostasis in the brain (Garcı´a-
Ca´ceres et al., 2016). Insulin is also an important neuro-
modulator that plays an essential role in synaptic plasticity
and differentiation (Chiu et al., 2008; Kennedy et al.,
2013). Insulin regulates synaptic transmission by promoting
the translocation of N-methyl-D-aspartate (NMDA) recep-
tors to the cell membrane (Skeberdis et al., 2001) and the
internalization of -amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptors (Lin et al., 2000).
Moreover, insulin and insulin receptor levels are highly ex-
pressed in regions involved in learning and memory, like
the hippocampus, where it facilitates long-term potentiation
through the activation of the MAPK/ERK pathway (Zhao
et al., 2011).
Considering the relevance of insulin for the maintenance
of brain homeostasis and function, it is not surprising that
alterations in insulin signalling pathways have been asso-
ciated with Alzheimer’s disease. Patients with Alzheimer’s
disease present reduced CSF-to-plasma insulin ratio (Gil-
Bea et al., 2010) and post-mortem analysis of Alzheimer’s
disease brains has shown downregulated insulin and insulin
receptor mRNA levels, together with insulin and insulin
receptor substrate 1 (IRS1) signalling impairments (Rivera
et al., 2005; Talbot et al., 2012). Furthermore, analysis of
neural origin-enriched plasma exosomes has shown an en-
richment in pSer312-IRS-1 (associated with ineffective in-
sulin signalling) in Alzheimer’s disease patients
(Kapogiannis et al., 2015; Mullins et al., 2017). The
notion of Alzheimer’s disease being a metabolic disorder
has gained relevance in the past few years, as increasing
evidence suggests that insulin resistance and decreased cere-
bral glucose utilization are early pathogenic events in the
disease. In the past decade, some authors have further sug-
gested that Alzheimer’s disease could be a brain-speciﬁc
type of diabetes (Steen et al., 2005; de la Monte and
Wands, 2008). Indeed, ﬂuorodeoxyglucose (FDG)-PET stu-
dies have shown that insulin resistance is associated with
decreased regional glucose metabolism, especially in the
medial temporal lobe, that was associated with worse per-
formance in memory tests (Willette et al., 2015a).
Insulin signalling impairment leads to alterations in
energy metabolism and increased oxidative and endoplas-
mic reticulum stress (De La Monte et al., 2012), all
common features of neurodegenerative disorders like
Alzheimer’s disease. Furthermore, deﬁcits in insulin signal-
ling are a contributing factor to tau hyperphosphorylation
and neuroﬁbrillary tangle (NFT) formation (Calvo-Ochoa
et al., 2014). Insulin regulates tau phosphorylation by mod-
ulating the activity of tau kinases, including glycogen syn-
thase kinase 3 beta (GSK3b) through the
phosphatidylinositol kinase (PI3K)/protein kinase B (AKT)
signalling pathway (Schubert et al., 2004; Avila, 2008; Liu
et al., 2008; Bian et al., 2016). Insulin resistance leads to
aberrant GSK3b activation (Schubert et al., 2004) and in-
hibition of AMPK-mediated tau de-phosphorylation (Kim
et al., 2015), triggering tau hyperphosphorylation.
Moreover, the decrease in glucose metabolism as a conse-
quence of insulin resistance leads to tau O-GlcNAcylation
downregulation, contributing to tau hyperphosphorylation
(Liu et al., 2004, 2009; Yuzwa and Vocadlo, 2014).
Insulin-signalling deﬁciencies have also been shown to pre-
dict the pathological deposition of amyloid-b, another key
feature in Alzheimer’s disease (Willette et al., 2015b).
Insulin promotes the non-amyloidogenic processing of
amyloid precursor protein (APP) by regulating its phos-
phorylation, thus, defects in insulin signalling can increase
pathological amyloid-b accumulation (Pandini et al., 2013).
Furthermore, insulin and amyloid-b are both substrates of
insulin-degrading enzyme (IDE). Insulin regulates IDE by
increasing its protein levels, thus deﬁcits in insulin signal-
ling lead to deﬁcient amyloid-b degradation (Zhao et al.,
2004, 2009).
Despite the fact that insulin has been shown to be essen-
tial for neuronal function and memory formation and that
deﬁciencies in insulin signalling have been directly linked to
some of the major hallmarks of neurodegenerative dis-
orders like Alzheimer’s disease, to date, little is known
about insulin state and distribution under pathological con-
ditions in the brain. Here, we report that insulin is accu-
mulated and retained as insoluble oligomers in tau-bearing
neurons in Alzheimer’s disease and several of the most
prevalent tauopathies. Intraneuronal insulin accumulation
is driven by tau hyperphosphorylation and results in insulin
resistance. The implications of these ﬁndings to the patho-
genesis of tauopathies and their relevance for proposed in-
sulin-based therapies are discussed.
Materials and methods
Human brain samples
Parafﬁn-embedded brain slices from the cingulate cortex, fron-
totemporal cortex and hippocampus of non-diabetic patients
with Alzheimer’s disease, patients with deﬁnite Alzheimer’s
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disease and diabetes mellitus, control patients and control pa-
tients with diabetes mellitus were obtained from the CIEN
foundation Brain Bank (Spain). Parafﬁn-embedded hippocam-
pal slices from Alzheimer’s disease patients with Braak I–II,
Alzheimer’s disease Braak III–IV, Alzheimer’s disease Braak
V–VI, hippocampal slices of patients with argyrophilic grain
disease (AGD), patients with progressive supranuclear palsy
(PSP) (hippocampus and striate nucleus) and patients with
corticobasal degeneration (CBD) (hippocampus and frontal
cortex) were provided by the Bellvitge University Hospital
(Spain). Fresh frozen human brain specimens of different re-
gions were obtained from the Harvard Brain Tissue Resource
Center (MA, USA). The post-mortem intervals, neuropatho-
logical and clinical diagnoses, age and gender distribution as
well as diagnostic grouping are presented in Table 1.
Mice tissue
Sagittal sections (30 mm) of brain tissue were obtained from
3 month tau-KO (Charles Rivers) and 10-month-old PS19
Table 1 Demographic data of the cases studied
Diagnosis Age Gender PMI (h) Braak stage DM APOE Analysis Source
Ctrl_1 81 M 23.33 II - - ELISA, WB Harvard Brain Tissue Resource Center (USA)
Ctrl_2 72 M 27.67 I – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
Ctrl_3 82 F 24.42 II – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
Ctrl_4 73 F 24.88 I – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
Ctrl_5 71 F 22.00 I – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
Ctrl_6 82 – 9 I – E3/E3 IP/WB Karolinska Institutet Brain Bank (Sweden)
Ctrl_7 80 F 7 I – E3/E3 IP/WB Karolinska Institutet Brain Bank (Sweden)
Ctrl_8 83 F 9 I – E3/E3 IP/WB Karolinska Institutet Brain Bank (Sweden)
Ctrl_9 75 M 5 I ND – IF, IHC CIEN foundation (Spain)
Ctrl_10 78 F 3 III ND – IF CIEN foundation (Spain)
Ctrl_11 88 M 3 II ND – IF CIEN foundation (Spain)
Ctrl_12 74 F 7 – ND – IF, IHC CIEN foundation (Spain)
Ctrl_13 – – 2 – DM – IF CIEN foundation (Spain)
Ctrl_14 – – 2 – DM – IF CIEN foundation (Spain)
AD_1 76 F 8 VI – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_2 68 M 8.62 VI – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_3 85 F 25.26 VI – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_4 82 M 12.88 V – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_5 71 F 27 V – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_6 84 F 25.50 V – – ELISA, WB Harvard Brain Tissue Resource Center (USA)
AD_7 72 F 8 V – – IP/WB Karolinska Institutet Brain Bank (Sweden)
AD_8 70 F 12 V – – IP/WB Karolinska Institutet Brain Bank (Sweden)
AD_9 76 – 4 VI – E3/E4 IP/WB Karolinska Institutet Brain Bank (Sweden)
AD_10 74 F 4 V DM E3/E4 IF CIEN foundation (Spain)
AD_11 82 F 4.3 V DM E3/E4 IF CIEN foundation (Spain)
AD_12 80 M – V DM E3/E4 IF CIEN foundation (Spain)
AD_13 86 F 3 V ND E3/E3 IF, IHC CIEN foundation (Spain)
AD_14 84 F 3 V ND E3/E3 IF, IHC CIEN foundation (Spain)
AD_15 84 F 6 VI ND E3/E3 IF CIEN foundation (Spain)
AD_16 52 F 11 I–II – – IF Bellvitge University Hospital (Spain)
AD_17 77 F 17.40 I–II – – IF Bellvitge University Hospital (Spain)
AD_18 69 F 11.40 I–II – – IF Bellvitge University Hospital (Spain)
AD_19 72 F 16.10 III–IV – – IF Bellvitge University Hospital (Spain)
AD_20 89 M 3.20 III–IV – – IF Bellvitge University Hospital (Spain)
AD_21 69 F 8 III–IV – – IF Bellvitge University Hospital (Spain)
AD_22 96 F 17.35 V–VI – – IF Bellvitge University Hospital (Spain)
AD_23 73 F 17.45 V–VI - - IF Bellvitge University Hospital (Spain)
AD_24 75 M 21.14 V–VI - - IF Bellvitge University Hospital (Spain)
PSP_1 56 M 11.25 Advanced - - IF Bellvitge University Hospital (Spain)
PSP_2 65 M 8.45 Advanced - - IF Bellvitge University Hospital (Spain)
CBD_1 83 M 13.35 Advanced - - IF Bellvitge University Hospital (Spain)
AGD_1 79 M 24.30 Advanced - - IF Bellvitge University Hospital (Spain)
AGD_2 63 M 10.20 Advanced - - IF Bellvitge University Hospital (Spain)
AGD_3 82 F 4 Advanced - - IF Bellvitge University Hospital (Spain)
I-VI = Braak stages; AD = Alzheimer disease; Ctrl = Control; DM = diabetes mellitus; F = females; IF = immunofluorescence; IHC = immunohistochemistry; IP = immunoprecipitation;
M = males; ND = non-diabetic; PMI = post-mortem interval; WB = western blot; – = no information available.
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mice encoding the human P301S mutation (The Jackson
Laboratory, 008169). P301S mice were back-crossed for
eight generations with C57BL6/J mice. Wild-type (WT) ani-
mals (C57BL6/J) of respective similar ages were used as con-
trols. The P301S mouse model carries a mutant (P301S)
human MAPT gene encoding T34-tau isoform (1N4R)
driven by the mouse prion-protein promoter (Prnp) on a
B6C3H/ F1 genetic background (Yoshiyama et al., 2007).
Tau-KO was generated by replacing exon 1 of the mouse
TAU gene with a neomycin resistance cassette34 (Dawson
et al., 2001). All mice were housed at the Centro de Biolog|a
Molecular ‘Severo Ochoa’ animal facility. Mice were housed
four per cage with food and water available ad libitum and
maintained in a temperature-controlled environment on a 12/
12 h light-dark cycle with light onset at 07:00 h. Animal hous-
ing and maintenance protocols followed the guidelines of
Council of Europe Convention ETS123, recently revised as
indicated in the Directive 86/609/EEC. Animal experiments
were performed under protocols (P15/P16/ P18/P22) approved
by the Centro de Biolog|a Molecular Severo Ochoa
Institutional Animal Care and Utilization Committee (Comite
de Etica de Experimentacio´n Animal del CBM, CEEA-CBM,
Madrid, Spain).
Cell lines
SH-SY5Y human neuroblastoma cell line was obtained from
the American Type Culture Collection (ATCC). Stable full-
length tau (Tau 441) overexpressing SH-SY5Y (SH-SY5Y-
Tau) cells were created as described by Monroy-Ramı´rez
et al. (2013).
Cells were grown in a 1:1 Dulbecco’s modiﬁed Eagle
medium: Nutrient Mixture F-12 (DMEM/F-12) (Thermo-
Fisher) supplemented with 10% foetal bovine serum
(Thermo-Fisher) and incubated at 37C in a humidiﬁed 5%
CO2-containing atmosphere. Cells were seeded (150 000 cells/
cm2) 24 h before the experiments.
Primary cultures
Cortical neurons in primary culture were prepared from foetal
(embryonic Day 18) Wistar rats (Jackson). Cells were seeded
(25 000 cells/cm2) in Neurobasal media (Thermo Fisher), sup-
plemented with 2% B-27 (Thermo Fisher), 2mM
GlutaMAXTM (Thermo Fisher), 100 units/ml penicillin and
100mg/ml streptomycin (PEST, Thermo Fisher), and incubated
at 37C in a humidiﬁed 5% CO2-containing atmosphere. All
experiments were performed after 10 days in culture. All the
experiments involving primary cultures were approved by
Karolinska Institute’s regional ethical committee.
Cell treatments
For okadaic acid treatments, media was removed and replaced
with complete media (Neurobasal, 2% B-27, 2 mM
GlutaMAXTM) with 250 nM of okadaic acid (O9381, Sigma-
Aldrich) prepared in DMSO (O9381, Sigma-Aldrich). Media
with the same ﬁnal concentration of DMSO was used as a
control. The cells were then incubated for 1 h at 37C in a
humidiﬁed 5% CO2-containing atmosphere.
Cell transfections
Short interfering RNA (siRNA) transfections in rat cortical
neurons in primary culture were performed using the reagent
DharmaFECTTM (Thermo Fisher) following the manufac-
turer’s instructions. Tau siRNA (50 nM) (L-089500-02-0005;
Darmacon) and DharmaFECTTMwere incubated separately for
5min in Neurobasal complete media. They were then mixed
and incubated for 20min. The Darmafect-siRNA mix was then
added to the cells. Transfection controls were performed with
a non-targeting siRNA (D-001810-10-05 Darmacon).
Experiments were performed after 72 h of transfection when
tau silencing was up to 50%.
SH-SY5Y cells were transfected with 1 mg/ml plasmid vectors
using Lipofectamine 3000 reagent (Thermo Fisher), following
the manufacturer’s instructions. Plasmids encoding GFP-tagged
human tau (pRK5-EGFP-Tau, Addgene plasmid #46904),
GFP-tagged pseudo-phosphorylated tau (pRK5-EGFP-Tau
E14, Addgene plasmid #46907) and GFP-tagged phospho-
null tau (pRK5-EGFP-Tau AP, Addgene plasmid #46905)
were a gift from Karen Ashe. pRK5-EGFP-Tau plasmid con-
tains 4R0N human tau sequences, pRK5-EGFP-Tau E14 and
pRK5-EGFP-Tau AP contain human tau sequence with muta-
tions in serine and proline amino acid residues (T111, T153,
T175, T181, S199, S202, T205, T212, T217, T231, S235,
S396, S404 and S422) to glutamate (E14) or alanine (AP)
(Hoover et al., 2010). Transfections with pcDNA 3 were
used as control. Cells were used for the experiments 48 h
after transfection.
Immunofluorescence
Cells were seeded in poly-D-lysine-coated round glass cover-
slips. After the treatments, they were ﬁxed in 4% PFA for
10min. Fixed cells were then blocked for 30min in 1%
bovine serum albumin (BSA), 0.1% TritonTM X-100, phos-
phate-buffered saline (PBS, Thermo Fisher) and incubated
with the primary antibody overnight at 4C. The antibodies
used were Insulin (1:300; ab7842, Sigma-Aldrich) and AT180
(1:500; NB100-82249, Novus Biologicals). The day after, the
cells were washed with PBS and incubated with the secondary
antibody in PBS for 1 h at room temperature. The secondary
antibodies used were Alexa Fluor 488 goat anti-guinea pig
(1:1000, Invitrogen corporation) and Alexa Fluor 633 goat
anti-rabbit (1:1000, Invitrogen corporation). DAPI was used as
nuclear staining. Cells were then washed and mounted with
ProLong Gold Antifade Reagent (Thermo Fisher).
Parafﬁn-embedded brain slices (14 mm) were deparafﬁnized
by xylene (twice, 10min each) followed by 90% ethanol
(twice, 10min each), 70% ethanol (10min) and ﬁnally distilled
H2O (10min) incubations. Antigen retrieval was later per-
formed using the DIVA NxGen decloaker and DIVA reagent
(DV2004MX, Biocare Medical) for 30min at 110C in a
Decloaking ChamberTM NxGen (DC2012, Biocare Medical).
Brain slices were then permeabilized in PBS, 0.1% TritonTM
X-100 for 30min. They were then blocked with PBS, 0.05%
TritonTM X-100, 10% goat serum for 30min and incubated
with the primary antibody in PBS, 0.05% TritonTM X-100,
10% goat serum overnight at 4C. The antibodies used were
Insulin (1:300; ab7842, Sigma-Aldrich and 1:100; Ab909, Bio-
YEDA), AT180 (1:500; NB100-82249, Novus Biologicals),
GFAP (1:300; 556330, BD Pharmigen), Tau-1 (1:300;
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MAB3420, Sigma-Aldrich) and AT100 (1:300; MN1060,
Thermo Fisher). The day after, slices were washed in PBS
and incubated with secondary antibodies in PBS for 1 h and
30min at room temperature. The secondary antibodies used
were Alexa Fluor 488 goat anti-guinea pig (1:1000,
Invitrogen), Alexa Fluor 633 goat anti-guinea pig (1:1000,
Invitrogen corporation), Alexa Fluor 546 goat anti-mouse
(1:1000, Invitrogen corporation), Alexa Fluor 633 goat
anti-rabbit (1:1000, Invitrogen corporation) and Alexa
Fluor 405 goat anti-mouse (1:1000, Invitrogen). DAPI was
used as nuclear staining. After incubations with secondary
antibodies we stained with Milli-MarkTM FluoroPan
Neuronal Marker-Alexa488 conjugate (MAB2300X,
Millipore). Afterwards, the slices were washed in PBS. To elim-
inate lipofuscin autoﬂuorescence, eliminator reagent (2160,
Millipore) was used following the manufacturer’s instructions.
Finally, they were mounted with ProLong Gold Antifade
Reagent (Thermo Fisher).
Avidin-biotin complex staining
Parafﬁn-embedded slices (4mm) were deparafﬁnized by xylene
(twice, 10min each) followed by 90% ethanol (twice, 10min
each), 70% ethanol (10min) and ﬁnally distilled H2O (10min)
incubations. Afterwards, antigen retrieval was performed using
the DIVA NxGen decloaker and DIVA reagent (DV2004MX,
Biocare Medical) for 30min at 110C. Brain slices were then
permeabilized in PBS, 0.1% TritonTM X-100 for 30min.
Endogenous peroxidase activity was blocked by 5min incuba-
tion with a peroxidase-blocking reagent (K4010, Dako). They
were then blocked with PBS, 0.05% TritonTM X-100, 10%
goat serum for 30min and incubated with insulin primary
antibody (1:300; ab7842, abcam) in PBS, 0.05% TritonTM
X-100, 10% goat serum overnight at 4C. The day after
slices were washed in PBS and incubated with the biotinylated
secondary antibody (1:1000; BA-7000, Vector Laboratories)
for 1 h and 30min at room temperature. The slices were
then washed with PBS and incubated for 30min with avidin-
biotin complex (ABC) reagent (PK-6100, Vector Laboratories).
The samples were then incubated in liquid DAB + chromogen
solution for detection (K4010, Dako). The reaction was
stopped by H2O2 washing. Afterwards the tissue was dehy-
drated by sequential incubations with 70% ethanol (twice,
3min), 90% ethanol (10min) and xylene (twice, 10min).
Finally, they were mounted with DEPEX.
Imaging
Confocal imaging was performed with a Zeiss LSM 510
META confocal laser scanning system. The ﬂuorescence was
recorded sequentially in separate channels with Plan-
Apochromate 20 (NA, 0.8), 40 (NA, 1.2) oil and
100 (NA, 1.45) oil objectives. Image processing was per-
formed with the included ZEN software. Cell quantiﬁcations
were performed with Neurolucida. Fluorescence intensity was
measured with the ImageJ 1.383 software (NIH, MA, USA).
Super-resolution structured illumination microscopy (SIM)
was performed at the Super-Resolution Microscopy Science
for Life Laboratory (Stockholm, Sweden) on a Carl Zeiss
Elyra PS.1 microscope. This method consists of generating a
grid by illuminating the sample with specially structured exci-
tation light. Afterwards it is processed to generate a
reconstruction with improved resolution (Gustafsson, 2000).
It can resolve an eight times smaller volume than conventional
confocal microscopy without using special ﬂuorophores, and
has been shown to be the most suitable super-resolution tech-
nique for imaging densely packed structures, as is the case with
NFTs (Schermelleh et al., 2010; Wegel et al., 2016). The ob-
jective used was an oil Plan-Apochromate 63 (NA, 1.40).
Emission was collected sequentially through appropriate di-
chroic mirrors and band pass ﬁlters set at 570–650 nm
(561 nm excitation) and 495–575 nm (488 nm excitation).
SIM processing was done with the included ZEN software
with selection of automatic settings for evaluation of the raw
data (i.e. theoretical PSF, selection of noise ﬁlter setting, fre-
quency weighting, baseline settings etc.) (Komis et al., 2015).
The optimal grid size was automatically assigned to each
wavelength by the Zeiss Zen software, and the grid was
rotated ﬁve times at ﬁve phases for each image. After evalu-
ation, the SIM images were checked for possible artefacts (e.g.
honey comb patterns of intensity in the image) so appropriate
selections of evaluation settings were applied. Calibration on
40 nm beads generated a lateral precision of97  4 nm at
488 nm excitation.
Optical imaging was performed on a Nikon Eclipse E800M
optical microscope with a Plan-Apochromate 20 (NA, 0.75)
objective.
Western blot
After the treatments, cells were lysed in 1% TritonTM X-100,
150mM NaCl, 1mM EDTA, 1mM EGTA, 50mM Tris; pH
7.5, supplemented with phosphatase and protease inhibitors
(Sigma-Aldrich). The cell extracts were then subjected to
sodium dodecyl sulphate (SDS) polyacrylamide gel electrophor-
esis (MiniProtean, Bio-Rad) and transferred to a nitrocellulose
membrane (GE healthcare). Membranes were blocked in 5%
non-fat milk for 1 h at room temperature and blotted with the
primary antibodies overnight at 4C. Antibodies used were
Insulin (1:2000; NBP1-45662, Novus Biologicals), Total Tau
(1:1000; A0024, Dako), AT180 (1:2000; NB100-80249,
Novus Biologicals), Insulin degrading enzyme (IDE) (1: 1000;
sc-27265, Santa Cruz Biotechnology), Insulin receptor beta
(total IR) (1:1000; Cell Signalling) and phospho Akt (P-Akt)
(1:1000; 9271S, Cell Signalling). Actin (1:5000; A2066,
Sigma-Aldrich) or GAPDH (1:2000; ADI-CSA-335, Enzo)
were used as loading controls. The day after, they were incu-
bated with horseradish peroxidase-conjugated goat anti-mouse
(1:5000; NA941V, GE healthcare), goat anti-rabbit (1:5000;
NA934V, GE healthcare) or donkey anti-goat (1:5000;
PI9500, Vector Laboratories) antibodies for 1 h at room tem-
perature. Signal detection was performed with an enhanced
chemiluminescence kit (ECL detection system, Amersham
Biosciences). The quantiﬁcation of the bands was performed
with the ImageJ 1.383 software and calculated from the op-
tical density multiplied by the area for each band. The values
were then normalized with their corresponding loading control
(actin or GAPDH).
Immunoprecipitation
Insulin (1:200; NBP1-45662, Novus Biologicals) or A11 pan-
oligomers (1:100; AHB0052, Invitrogen) antibodies were incu-
bated with 20 ml of Dynabeads protein A (Thermo Fisher) in
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an orbital shaker (overnight, 4C). Afterwards the antibody-
beads conjugate was washed with PBS and incubated with the
protein lysates (0.25 mg/ml, obtained as detailed in the western
blot section) overnight at 4C in an orbital shaker. The fol-
lowing day, an aliquot of the supernatant was retired for using
as loading control (input). The remaining supernatant was
then removed and the beads-antibody-protein pellet was
washed three times with PBS. Finally, the proteins were
eluted from the antibody by incubation in loading buffer
(10min at 70C), subjected to native PAGE (for insulin immu-
noprecipitation) or SDS (for A11 immunoprecipitation) poly-
acrylamide gel electrophoresis, transferred to a nitrocellulose
membrane and blotted against A11 (insulin immunoprecipita-
tion) or insulin (A11 immunoprecipitation). To determine the
speciﬁcity of the A11 antibody for oligomeric forms of insulin,
three controls were used in the immunoprecipitation process:
PBS, 1 mg/ml human recombinant insulin (91077C, Sigma-
Aldrich) and the same concentration of human recombinant
insulin that had been previously incubated for aggregation
(24 h, 37C in an orbital shaker). The presence of insulin ag-
gregates in this sample was conﬁrmed by thioﬂavin ﬂuores-
cence assays (data not shown).
Preparation of human samples for
ELISA analysis
Preparation was done from 100mg of frozen human hippo-
campus of control (n = 4) and Alzheimer’s disease (n = 5) cases
(Table 1) homogenized in 600 ml PBS (pH 7.4) using a pestle
motor homogenizer (Sigma-Aldrich). Homogenization was per-
formed at + 4C in presence of protease and phosphatase in-
hibitor cocktails (Sigma-Aldrich) until completely dissolved
(1min at full speed). The whole volume of brain homogenate
was centrifuged at 125 000g for 20min. The supernatant (PBS
fraction) was collected and the pellet dissolved in 150ml 1%
SDS in PBS and centrifuged at 125 000g for 20min at room
temperature. This step was repeated until six SDS soluble frac-
tions were obtained. The SDS supernatants were pooled for
subsequent analysis (SDS fraction). The remaining pellet of
insoluble material was immediately dissolved in 80% formic
acid (FA), vortexed for 30 s followed by 20min sonication in a
20C water bath. After 25 000g centrifugation for 10min, the
supernatant was collected (formic acid fraction). All samples
were stored at –20C until further analysis. Immediately before
the ELISA measurements, formic acid soluble fractions were
neutralized in 2M Tris-HCl, pH 14.0 and mixed with
10 radio-immunoprecipitation assay (RIPA) buffer (750mM
NaCl/5.0% NP-40/2.5% sodium deoxycholate/0.5% SDS/
250mM Tris–HCl, pH 8.0) to avoid peptide aggregation.
Enzyme linked immunosorbent assay
Insulin concentrations in PBS, SDS and formic acid fractions
were measured in duplicates by human Insulin ELISA kit
(Merck Millipore) following the manufacturer’s instructions.
A volume of 100ml of undiluted PBS and SDS samples and a
10-fold dilution of the formic acid samples were loaded to the
ELISA plate and incubated at room temperature for 90min on
orbital shake (400 rpm). After a series of washing with wash
buffer supplied in the kit, human insulin detection antibody
was added to each well and incubated for 1 h at room
temperature. After washing, the wells were incubated with
enzyme solution for 30min and the amount of insulin was
subsequently quantiﬁed by incubating with 50 mM Amplex
UltraRed reagent (Invitrogen) for 30min, followed by detec-
tion of the ﬂuorescent signal using a 544 nm excitation ﬁlter
and 590nm emission ﬁlter in a microplate reader (TECAN).
The data were normalized to protein content in each fraction.
Total insulin without normalization is illustrated in
Supplementary Fig. 1F.
Protein determination
Protein contents were determined using Pierce BCA kit (Thermo
Scientiﬁc) according to the manufacturer’s instructions.
Relative quantification in real time
Total RNA was isolated using the RNeasy mini kit (Qiagen)
including DNAse treatment (RNase-Free DNase Set, Qiagen).
RNA samples were run on agarose gels to conﬁrm no genomic
DNA contamination and the purity was assessed by RNA 260/
280 ratio. Total RNA (300 ng) was then reverse transcribed
using High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). To perform real time RT-qPCR assays, we used
the relative standard method supplied by Applied Biosystem
(Applied Biosystems, 2004). Serial dilutions of a reverse tran-
scription product (cDNA) from rat brain were carried out to
obtain standards curves containing 100, 50, 5, 0.5, 0.05 ng/ml,
and run by duplicate in the same PCR plate as the experimen-
tal samples. PCR reactions were performed to quantify both
target gene (Ins2 and InsR) and endogenous gene (Gapdh)
sequences in three independent experiments. Relative quanti-
ties of Slc2a4 (GLUT4), Ins2, Insr mRNA and Gapdh mRNA
were determined by comparing the threshold cycle (Ct) of
each sample with that of a standard curve run on the same
PCR plate. Thermocycling and ﬂuorescence detection was
performed according to the TaqMan Gene Expression
Assays Protocol using an ABI PRISM 7000 Sequence
Detection System with a total volume of 20 ml in each well
containing 10 ml of PCR Master Mix (Applied Biosystems),
2 ml of cDNA (corresponding to 15 ng of total RNA), 1 ml of
each TaqMan Gene Expression Assays primer (Applied
Biosystems), and 7 ml molecular grade RNase-free water
(Dharmacon GE Lifesciences, B-003000-WB-100). Relative
quantities of target genes were adjusted to relative quantities
of Gapdh and normalized to controls conditions (set at
100%). Values are reported as the mean  SEM (standard
error of the mean) of triplicate experiments. ***P50.001;
**P50.01; *P5 0.05 indicate values that signiﬁcantly differ
from controls.
Flow cytometry
For FITC-Insulin uptake experiments neurons in primary cul-
ture were incubated for 1 h in Neurobasal media (Thermo
Fisher), supplemented with 2% B-27 minus insulin (Thermo
Fisher), 2mM GlutaMAXTM (Thermo Fisher) and 400 nM
FITC-labelled insulin (I3661, Sigma-Aldrich), either in the
presence or absence of okadaic acid (250 nM), at 37C in a
humidiﬁed 5% CO2-containing atmosphere. Neurons where
then detached with 5mM EDTA. After centrifugation (500g,
5min) they were resuspended in PBS and insulin ﬂuorescence
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intensity (an average of 20000 cells per condition in ﬁve differ-
ent experiments) was measured on a FACScaliburTM ﬂow cyt-
ometer (15 mW argon ion laser tuned at 488nm; CellQuest
software, Becton Dickinson Biosciences).
Statistical analysis
Measurements were carried out in duplicate or triplicate. The
results are expressed as mean  SEM values for three different
cell culture/clinical sample preparations. The statistical analysis
of the results was performed by one-way analysis of variance
(ANOVA), followed by the least signiﬁcant difference multiple
range test. In all cases, P50.05 was considered to be signiﬁ-
cant (*P5 0.05, **P5 0.01).
Results
Insulin is accumulated in
hyperphosphorylated tau-bearing
neurons in Alzheimer’s disease
Regarding the close relationship between insulin resistance
and Alzheimer’s disease, we ﬁrst aimed to determine if in-
sulin distribution was affected in Alzheimer’s disease brains
by performing immunohistochemical staining for insulin in
different areas (cingulate cortex, temporal cortex and
hippocampus) of control (Cases Ctr_10–12) and
Alzheimer’s disease (Cases AD_13–15) brains. These areas
were selected according to the progression of tau pathology
in Alzheimer’s disease, which initiates in the entorhinal
cortex, continues in the hippocampus and reaches neocor-
tical regions in the most advanced stages of the disease
(Braak and Braak, 1996). As seen in Fig. 1A, insulin immu-
noreactivity was widely distributed and showed stronger
staining in Alzheimer’s disease brains compared to controls,
particularly in the hippocampus (CA1–CA3). In neocortical
areas, similar results were found in the temporal cortex
(layer III), being less evident in the cingulate cortex
(Supplementary Fig. 1A). Double immunoﬂuorescence ana-
lysis of the CA1 hippocampal layer for insulin, glial ﬁbril-
lary acidic protein (GFAP) and FluoroPan neuronal marker
revealed that Alzheimer’s disease brains (Cases AD_14–15
and 22) had higher insulin staining in neurons compared to
controls. In contrast, control brains (Ctr_9–11) showed
stronger insulin immunoreactivity in astrocytes compared
to neurons and no differences were found in insulin stain-
ing in astrocytes in Alzheimer’s disease compared to con-
trols (Fig. 1B). As shown in Supplementary Fig. 1C, insulin
was not present in extracellular tau deposits or thioﬂavin S-
positive plaques (data not shown).
To further explore if brain insulin accumulation follows
tau pathology progression, we performed immunoﬂuores-
cence studies in hippocampal slices from patients in early to
late stages of the disease (Braak I–VI). As shown in Fig. 1C
and Supplementary Fig. 1D, insulin immunoﬂuorescence
intensity was signiﬁcantly increased in the CA1 layer of
the hippocampus in initial (Braak I–II) through advanced
stages of Alzheimer’s disease (Braak V–VI) (Ctr_10–14 and
Cases AD_16–24). It is noteworthy that we performed
immunohistochemical studies using a different insulin anti-
body (Ab909) with comparable results (Supplementary Fig.
1B).
Given that type 2 diabetes mellitus (T2DM) and hyper-
insulinemia are known risk factors for Alzheimer’s disease
(Luchsinger et al., 2004; Xu et al., 2004), we explored the
possible relationship between T2DM and brain insulin ac-
cumulation in a subset of samples from controls (Ctr_9–14)
and Alzheimer’s disease (AD_10–15) individuals with and
without T2DM. To do so, we established criteria for basal
insulin ﬂuorescence intensity (arrows in Supplementary Fig.
1E), the cells where insulin staining was found to be stron-
ger were considered as cells with increased insulin levels
(asterisks in Supplementary Fig. 1E). The total number of
cells was counted per image ﬁeld in a total of three images
from the CA1 layer of the hippocampus per patient, and
each cell (70 cells on average) classiﬁed depending on its
insulin status. As shown in Fig. 1D, the percentage of cells
with accumulated insulin was signiﬁcantly increased in
Alzheimer’s disease patients regardless of T2DM status.
Furthermore, the number of neurons with accumulated in-
sulin was lower in control brains regardless of their T2DM.
We next investigated whether insulin accumulation
occurs in the same neurons bearing tau hyperphosphoryla-
tion. To detect tau pathology, we used AT180, an antibody
that recognizes hyperphosphorylated tau at T231. Figure
1E shows insulin and AT180 immunoreactivities in the
CA1 hippocampal layer of control and Braak V–VI. In
Alzheimer’s disease samples, insulin levels were higher in
AT180 positive neurons, especially in those with NFT-like
staining (Fig. 1E). As seen in Fig. 1F, quantiﬁcation of
immunoreactivities in layer III of the cingulate and tem-
poral cortices as well as hippocampal CA1 from
Alzheimer’s disease (AD_10–15) and controls (Ctr_9–12)
revealed that insulin accumulation was not present in all
neurons with NFT formations. Interestingly, the majority of
neurons with high insulin levels (80–90%) also showed
NFTs. Consistent with the ﬁndings showed in Fig. 1A and
Supplementary Fig. 1A, hippocampal neurons displayed
higher insulin accumulation (60% of total neurons) com-
pared to neocortical areas (30%) (Fig. 1F). Quantiﬁcation
of insulin status was performed using the criteria shown in
Supplementary Fig. 1E. Considering that AT180 has been
shown to be highly conserved in MAP2 (Xie and
Miyasaka, 2016), we performed additional staining with
another anti-hyperphosphorylated tau antibody (AT100)
and with total tau (Tau-1) in the hippocampus of control
and Alzheimer’s disease patients. In all the cases studied,
AT180 co-localizes with AT100 immunoreactivity, discard-
ing the exclusion of phospho-tau positive neurons, and pos-
sible artefacts due to the interaction of AT180 with MAP2
(Supplementary Fig. 2A). Furthermore, CA1-CA3 hippo-
campal neurons with NFT also showed increased Tau-1
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Figure 1 Insulin levels are increased in hyperphosphorylated tau-bearing hippocampal and cortical neurons in Alzheimer’s
disease. (A) ABC immunohistochemistry for insulin in human brain sections of the CA1, CA2 and CA3 layers of the hippocampus show
increased insulin staining in Alzheimer’s disease samples compared to controls. Scale bar = 100 mm. (B) Confocal microscopy images of insulin
(green), Pan-neuronal marker (red) and GFAP (red) in CA1 of control and Alzheimer’s disease patients. In neurons, insulin is increased in
Alzheimer’s disease and barely detectable in controls. In astrocytes, insulin immunoreactivity was detected both in controls and Alzheimer’s
disease. DAPI (blue) was used as nuclear marker. Scale bar = 25 mm. (C) Insulin fluorescence intensity quantification from confocal images in
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immunoreactivity in Alzheimer’s disease, suggesting tau
pathological accumulation (Supplementary Fig. 2B).
Insulin accumulates as oligomers in
the brain
We and others have previously reported decreased insulin
levels in the CSF of Alzheimer’s disease individuals (Gil-Bea
et al., 2010; Lee et al., 2013), which seems in apparent
contrast to the results presented above. To further clarify
this issue, we measured insulin levels in brain fractions of
different solubility. Based on a modiﬁed protocol for separ-
ating different forms of amyloid-b from human brain
(Sandebring et al., 2013), we extracted PBS (monomers
and soluble oligomers), SDS (water insoluble oligomers
and protoﬁbrils) and formic acid (large, ﬁbrillar structures
and insoluble oligomers) fractions from hippocampal brain
samples of controls (Ctrl_1–5) and Alzheimer’s disease
(AD_1–6) individuals and quantiﬁed insulin levels by
ELISA. Data were normalized to the protein content of
each fraction. Two cases (one control and one
Alzheimer’s disease) were excluded as outliers as they
were not within the interquartile range by41.5 of inter-
quartile ranges (Williamson et al., 1989).
As shown in Fig. 2A, the total pool of insulin in control
brains was mainly distributed in the PBS (51%) and SDS
(32%) fractions, while formic acid-enriched insulin ac-
counted for17%. Interestingly, a signiﬁcantly higher in-
sulin accumulation was detected in formic acid fractions
from Alzheimer’s disease cases compared to controls (Fig.
2B). No differences between groups were found in SDS-
soluble fractions. In the PBS fractions, we observed a
slight increase in the Alzheimer’s disease group that was
not signiﬁcant when normalized by total protein levels
(Supplementary Fig. 1F). It is worth noting that differences
in total protein content between Alzheimer’s disease and
control brains due to neuronal cell death, massive gliosis
and increased protein aggregation make proper data nor-
malization difﬁcult. Figure 2C shows the levels of the neur-
onal marker NeuN, the glial marker GFAP and actin in the
PBS and SDS fractions. As expected, there was a signiﬁcant
reduction in the number of neurons and extensive gliosis in
Alzheimer’s disease compared to controls (Fig. 2C).
Considering that we found accumulated insulin in
Alzheimer’s disease neurons, the increment in insulin
levels quantiﬁed in brain extracts by ELISA could be under-
estimating the real levels of its accumulation in neurons.
Our ELISA results showing increased insulin levels in
formic acid soluble fractions from Alzheimer’s disease
brains suggest accumulation of insulin in insoluble aggre-
gates or ﬁbrils in the disease. To further clarify this ﬁnding,
we performed additional immunoﬂuorescence experiments
and analysed the samples by SIM microscopy. As shown in
Fig. 2D, the pattern of insulin immunoreactivity in
Alzheimer’s disease samples does not correspond to
mature ﬁbrils. Moreover, insulin and phospho-tau (detected
by AT180) immunoreactivities do not co-localize suggesting
that insulin accumulation occurs independently of a phys-
ical interaction with phospho-tau oligomers or ﬁbrils. To
conﬁrm the presence of insulin oligomers in human brain,
we performed immunoprecipitation experiments with the
anti-pan-oligomer conformational antibody A11. A11 has
been used for detection of oligomeric structures, excluding
monomers, protoﬁbrils and ﬁbrils (Upadhaya et al., 2012).
It has been shown to detect human insulin, IAPP, -synu-
clein, polyglutamine, lysozyme and yeast prion oligomers
(Kayed, 2003). Immunoprecipitation with A11 followed
by blotting for insulin revealed the presence of insulin
oligomers in human brain homogenates (Fig. 2E) (brain
preparation corresponds to combined PBS and SDS frac-
tions). Human recombinant insulin, either fresh or incu-
bated (24 h, 37C) for oligomerization, was used as a
control. As seen in Fig. 2E (right blot), the IgG heavy
chain was detected at 50 kDa. In the sample with aggre-
gated insulin, a signal was detected at 25 to 45 kDa, cor-
responding to insulin oligomers. Insulin oligomers were
signiﬁcantly higher in Alzheimer’s disease compared to con-
trols (Fig. 2E). To conﬁrm these results, we performed
immunoprecipitation with an insulin antibody followed
by A11 blotting in non-denaturalizing conditions. As
shown in Supplementary Fig. 1G, Alzheimer’s disease sam-
ples showed increased levels of high molecular weight in-
sulin oligomers (4100 kDa) compared to controls.
Neuronal accumulation of insulin in
other tauopathies
Considering the strong relationship observed between
insulin accumulation and tau hyperphosphorylation
in Alzheimer’s disease brains, we next analysed this
Figure 1 Continued
individual cells (440 cells per patient) from CA1 of control and Alzheimer’s disease patients (Braak I–II; Braak III–IV; Braak V–VI) show that insulin
levels are increased along Alzheimer’s disease progression. (D) Percentage of cells (460 cells per patient) with basal versus increased insulin
staining in CA1 of control and Alzheimer’s disease patients with or without diabetes mellitus show that insulin accumulation is independent of the
diabetic condition. (E) Confocal microscopy images of immunofluorescence staining against phospho-tau (AT180, red) and insulin (green) in
hippocampal CA1 of control and Alzheimer’s disease patients show intraneuronal insulin accumulation in AT180-positive neurons in Alzheimer’s
disease. DAPI was used as nuclear marker. Scale bar = 25mm. (F) Percentage of cells that show hyperphosphorylated tau (AT180 positive),
increased insulin levels or both in cingulate cortex, temporal cortex and hippocampal CA1 of controls and Alzheimer’s disease. All data are
represented as mean values  SEM. ***P5 0.001 versus control, **P5 0.01 versus control, *P5 0.05 versus control. ABC = avidin-biotin
complex; AD = Alzheimer’s disease.
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Figure 2 Insulin accumulates as insoluble oligomers in brain. (A) Insulin distribution in fractions (PBS, SDS and formic acid-soluble) of
hippocampus from controls individuals. (B) Quantification of insulin in PBS, SDS and formic acid soluble fractions from hippocampus of controls
(n = 6) and Alzheimer’s disease (n = 5) patients shows increased insulin levels in the formic acid fraction in Alzheimer’s disease compared to
controls. Insulin levels were normalized per microgram of total protein in each fraction. (C) Immunoblotting for GFAP, NeuN and actin in the
10 | BRAIN 2017: Page 10 of 17 P. Rodriguez-Rodriguez et al.
(continued)
association in some of the most prevalent human tauopa-
thies: AGD, PSP and corticobasal degeneration (CBD).
AGD is a sporadic tauopathy characterized by the presence
of argyrophilic grains in the neuropil (Ferrer et al., 2008).
PSP is a type of parkinsonism that, unlike Alzheimer’s dis-
ease, presents additional tau deposits in glial cells both in
the hippocampus and in neocortical and subcortical areas
(Yoshida, 2006). Similar pathological features for tau accu-
mulation are observed in CBD (Yoshida, 2006). As seen in
Alzheimer’s disease, all these tauopathies presented intra-
neuronal accumulation of insulin in NFT-bearing neurons
in the CA1 layer of the hippocampus (Fig. 3A, B and
Supplementary Fig. 2). In AGD, no increased insulin immu-
noreactivity was observed in argyrophilic grains or neur-
onal processes (Fig. 3A). These results are in agreement
with our observations in Alzheimer’s disease samples,
where insulin staining was preferentially found in neuronal
somas (Fig. 1E). Co-immunostainings with AT100 showed
that all the cells labelled with AT180 also show AT100
immunoreactivity, discarding the possibility of identifying
MAP2 as phospho-tau-positive cells (Supplementary Fig.
2A). As observed in Alzheimer’s disease, CA1–CA3 hippo-
campal neurons with NFTs in AGD samples also showed
increased Tau-1 immunoreactivity (Supplementary Fig. 2B).
However, a different intracellular pattern between AT100
and AT180 was found in PSP and CBD (Supplementary
Fig. 2A and B).
Indeed, the regulation of tau kinases and phosphatases by
insulin is well known (Avila, 2008). To interrogate if tau
hyperphosphorylation and insulin accumulation are separ-
ate events or cause and consequence of a common neuro-
degenerative mechanism, we compared brains of P301S
mice—a model of tauopathy carrying a mutant (P301S)
human MAPT gene encoding T34-tau isoform (1N4R)
(Yoshiyama et al., 2007) with brains of wild-type (C57)
and Tau KO mice (Dawson et al., 2001). In P301S mice,
the development of tau pathology most likely occurs before
any other neuropathological event due to the genetic back-
ground, and thus we could assess if tau hyperphosphoryla-
tion leads to insulin accumulation. AT180, AT100 and
Tau-1 immunoreactivities were increased in CA1 hippo-
campal neurons together with insulin staining in P301S
compared to C57 and Tau KO mice, where insulin levels
where almost non-detectable (Fig. 3C and Supplementary
Fig. 3), suggesting that phospho-tau accumulation precedes
insulin accumulation in neurons.
Tau hyperphosphorylation results in
intraneuronal accumulation of insulin
oligomers and in insulin signalling
deficits
We next established two cellular models of tau hyperpho-
sphorylation; treatment of rat cortical neurons in primary
culture with the phosphatase inhibitor okadaic acid (OA;
250nM, 1h) (Pe´rez et al., 2002; Broetto et al., 2016) and
overexpression of full-length tau in SH-SY5Y human neuro-
blastoma cells (Monroy-Ramı´rez et al., 2013). As seen by
immunoblotting, immunoﬂuorescence and SIM microscopy,
okadaic acid treatment resulted in accumulation of insulin,
hyperphosphorylated tau and tau inside neurons (Fig. 4A
and B). In agreement with results seen in Alzheimer’s disease
and human tauopathies (Figs 2D and 3A), intracellular in-
sulin was not associated to tau ﬁbrils (Fig. 4B).
Immunoprecipitation with the A11 conformational antibody
revealed the presence of insulin oligomers in primary neu-
rons, which were increased upon okadaic acid treatment
(Fig. 4C). To clarify whether insulin accumulation was dir-
ectly dependent on tau hyperphosphorylation or just an
additional consequence of phosphatase inhibition, we per-
formed okadaic acid treatments under tau silencing condi-
tions. As observed in Fig. 4D, silencing tau by50%
prevented okadaic acid-induced insulin accumulation in
neurons. Furthermore, overexpression of full-length tau in
SH-SY5Y human neuroblastoma cells resulted in strong
intracellular accumulations of hyperphosphorylated tau
and insulin (Supplementary Fig. 4D). Okadaic acid-treated
neurons and Tau-SH-SY5Y cells show both increased tau
hyperphosphorylation and total tau accumulation. To clar-
ify if intracellular insulin accumulation was mediated by tau
hyperphosphorylation or its accumulation, we transfected
SH-SY5Y cells with plasmids encoding GFP-tagged human
tau (pRK5-EGFP-Tau), GFP-tagged pseudo-phosphorylated
tau (pRK5-EGFP-Tau E14) and GFP-tagged phospho-null
tau (pRK5-EGFP-Tau AP) (Hoover et al., 2010). As
shown in Supplementary Fig. 4I, insulin levels were signiﬁ-
cantly increased in pseudo-phosphorylated tau and total tau
over-expressing SH-SY5Y cells. Supplementary Fig. 4J
shows densitometric data of insulin normalized by tau
levels in each of the three tau-overexpressing models. Both
total tau and pseudo-phosphorylated tau signiﬁcantly
increased insulin levels when compared to phospho-null
tau overexpressing SH-SY5Y cells.
Figure 2 Continued
same PBS and SDS fractions used for ELISA in B. (D) SIM super resolution image shows that insulin (green) is not forming mature fibrils or binding
hyperphosphorylated tau (AT180, red) in Alzheimer’s disease. Scale bar = 10mm. (E) Immunoprecipitation of pooled PBS- and SDS- soluble
hippocampal samples from Alzheimer’s disease and control patients with the A11 anti-oligomer antibody followed by immunoblotting against
insulin. Alzheimer’s disease brains showed increased levels of insulin oligomers compared to controls (middle blot and histogram). PBS, human
recombinant insulin (INS) and the same concentration of in vitro aggregated human recombinant insulin (A-INS) were used as positive (A-INS) and
negative (PBS and INS) controls. Insulin oligomers are detected in bands between 20 and 50 kDa. An aliquot of each supernatant incubated for the
immunoprecipitation followed by actin immunoblotting was used as loading control (INPUT). Data are represented as mean values  SEM.
*P5 0.05 versus control, **P5 0.01 versus control, ***P5 0.001 versus control; n = 3. AD = Alzheimer’s disease; C = control; FA = formic acid.
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Figure 3 Insulin accumulates in human tauopathies and in P301S mice. (A) Confocal microscopy images of insulin (green), and
hyperphosphorylated tau (AT180, red) in CA1 hippocampal brain sections of controls, and patients with AGD, PSP or CBD. Scale bar = 150 mm.
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As shown in Fig. 4E, no signiﬁcant differences were
found in IDE protein levels between control and okadaic
acid treated neurons, suggesting that alterations in IDE ex-
pression, which could lead to deﬁciencies in insulin degrad-
ation, do not account for the results presented previously.
Therefore, we next aimed to determine whether the origin
of the high insulin levels observed in phospho-tau bearing
neurons was enhanced insulin uptake or increased insulin
synthesis. We used an antibody-free approach, incubating
rat primary neurons with FITC-insulin (400 nM) either in
the presence or absence of okadaic acid (250 nM, 1 h) and
measured intracellular insulin ﬂuorescence by ﬂow cytome-
try. As shown in Fig. 4F, after only 1 h treatment with
okadaic acid a modest but signiﬁcant increase in FITC-in-
sulin was found inside the cells. On the other hand, Q-PCR
analysis revealed that okadaic acid treatment did not
induce insulin synthesis, which was almost non-detectable
(data not shown).
We ﬁnally aimed to clarify the consequences of insulin
accumulation for insulin signalling in the cell. Western blot
analysis revealed a dramatic decrease in insulin receptor
expression and protein levels in tau-overexpressing SH-
SY5Y cells (Supplementary Fig. 4E and G). Furthermore,
these cells also show deﬁciencies downstream of the insulin
receptor in the expression levels of GLUT4 (Supplementary
Fig. 4F) and phosphorylation level of AKT (Supplementary
Fig. 4H). In contrast, these effects on insulin receptor were
not seen in primary neurons treated with okadaic acid
(250 nM) for 1 h (Supplementary Fig. 4A and B). To clarify
whether the decrease of insulin receptor levels was time-
dependent, we treated neurons with a milder concentration
of okadaic acid (10 nM) for a longer time (24 h). This con-
dition resulted in accumulation of phosphorylated tau
(Supplementary Fig. 4C), and a signiﬁcant decrease in in-
sulin receptor protein levels in neurons (Fig. 4G). To deter-
mine whether insulin receptor levels were downregulated as
a consequence of the okadaic acid-mediated enhancement
of insulin uptake, we incubated neurons for 24 h in insulin-
free media, either in the presence or absence of okadaic
acid. As shown in Fig. 4G, removing insulin from the
media resulted in increased insulin receptor levels in control
cells and prevented the okadaic acid-driven decrease in
insulin receptor levels observed in the presence of insulin
(Fig. 4H).
Discussion
Insulin signalling alterations and insulin resistance have
been proposed as contributors to Alzheimer’s disease
pathogenesis, but the molecular mechanisms behind this
association remain largely unknown. Here we report that
insulin accumulates intraneuronally together with hyper-
phosphorylated tau in Alzheimer’s disease and several tauo-
pathies. In Alzheimer’s disease, tau pathology initiates in
the entorhinal cortex, followed by the hippocampus and
reaching neocortical regions in the most advanced stages
of the disease (Braak and Braak, 1996). These different
stages of tau pathology correlate with the disease temporal
course and serve to classify its progression from very early
Alzheimer’s disease (Braak I–II) to severe Alzheimer’s dis-
ease (Braak V). We have found insulin accumulation in
CA1-CA3 hippocampal neurons from very early stages of
the disease (Braak I–II), to later disease stages in pyramid-
like cortical neurons in the temporal neocortex. No signiﬁ-
cant insulin accumulation was found in the cingulate
cortex, an area with late tau pathology in Alzheimer’s dis-
ease. Accumulation of insulin observed in Alzheimer’s dis-
ease brains occurs independently of whether the patient had
diabetes mellitus or not, which is in agreement with previ-
ous reports showing that peripheral and brain insulin levels
are independent, and brain insulin signalling alterations can
occur independently of the presence of clinical diabetes
(Talbot et al., 2012).
Insulin levels have been shown to be decreased in the
CSF of Alzheimer’s disease individuals (Gil-Bea et al.,
2010; Lee et al., 2013). These studies seem paradoxical
with the results presented here and with previous evidence
of increased general blood–brain barrier permeability in
Alzheimer’s disease (van de Haar et al., 2016) and
increased insulin blood–brain barrier permeability
described in Alzheimer’s disease mouse models (Poduslo
et al., 2001). A possibility to harmonize these seemingly
conﬂicting results would be that the accumulation of insu-
lin in Alzheimer’s disease brains resulted from increased
retention due to deﬁciencies in degradation or in clearance
mechanisms. Indeed, this is the case with amyloid-b whose
increased oligomeric and ﬁbrillary forms in Alzheimer’s dis-
ease brains are in contrast with its decreased levels in CSF
(Gil-Bea et al., 2010). Also, insulin is well known to
undergo amyloid oligomerization and ﬁbrillation in vitro,
which leads to a loss of its activity (Hjorth et al., 2016).
While some authors have reported the presence of insulin
aggregates in the injection area of diabetic patients (Mangla
et al., 2016), to date there are no reports showing endogen-
ous insulin aggregation in vivo. Our SIM results suggest
that insulin does not form mature ﬁbrils in Alzheimer’s
disease brains. However, quantiﬁcation of insulin levels
by ELISA in different solubility fractions revealed that
Figure 3 Continued
(B) Insulin fluorescence intensity quantification from confocal images in individual cells (440 cells per patient) from the CA1 layer of the
hippocampus of control, AGD, PSP and CBD patients show that insulin levels are significantly increased in these taupathies. (C) Confocal
microscopy images of brain slices from wild-type (C57), P301S and Tau KO mice stained with insulin (green) and hyperphosphorylated tau (AT180,
red) show that insulin is accumulated in the hippocampus in P301S mice, together with tau. Scale bar = 60mm.
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Figure 4 Tau hyperphosphorylation results in intraneuronal oligomerization of insulin and insulin resistance. (A) Immunoblotting
against insulin, phospho-tau (AT180) and total tau (TAU) shows tau hyperphosphorylation and accumulation accompanied by increased insulin
levels upon okadaic acid treatment (OA, 250 nM, 1 h) in primary rat cortical neurons. (B) SIM images of immunofluorescence against insulin
(green) and phospho-tau (AT180, red) in controls and in primary neurons treated with okadaic acid (OA, 250 nM, 1 h). Scale bar = 10mm.
(C) Immunoprecipitation with the A11 anti-oligomer antibody followed by SDS gel electrophoresis and insulin immunoblotting (right blot) shows
that insulin is generating oligomers upon okadaic acid treatment in cortical neurons in primary culture. Input samples blotted for insulin are shown
in the left blot. (D) Immunoblotting from cortical neuron lysates shows that siRNA silencing of Tau prevents the effect of okadaic acid on insulin
accumulation. Histograms show quantifications of Tau and insulin with data as percentage of control values. (E) Immunoblotting against IDE shows
no differences in protein levels in okadaic acid (250 nM, 1 h) treated cortical neurons compared to controls. Actin is shown as loading control.
(F) Flow cytometry assessment of FITC-insulin fluorescence intensity show that okadaic acid (250 nM, 1 h) induces an increase in FITC-insulin
levels in cortical primary neurons. (G) Immunoblotting against insulin receptor shows a significant decrease in protein levels in okadaic acid
(10 nM, 24 h) treated cortical neurons compared to controls. This effect is partially prevented in insulin-free (Ins) conditions. (H) Data from G
expressed as ratio of insulin receptor protein levels in okadaic acid-treated versus respective controls in each experiment, either in the presence
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insulin is accumulating in the insoluble fraction (formic
acid soluble) in Alzheimer’s disease brains. Moreover,
immunoprecipitation with the anti-pan-oligomer conform-
ational antibody A11 showed the presence of brain insulin
oligomers, with increased concentrations in Alzheimer’s dis-
ease samples. Immunoprecipitation with insulin followed
by A11 blotting under non-denaturalizing conditions con-
ﬁrmed the presence of increased levels of insulin oligomers
in Alzheimer’s disease samples. It has been previously
shown that SDS destroys amyloid-b native high molecular
weight aggregates (Yoshiike et al., 2008; Upadhaya et al.,
2012). This might explain the different molecular weight
for insulin oligomers observed under denaturalizing condi-
tions (Fig. 2E) and native PAGE (Supplementary Fig. 1G).
As seen for amyloid-b pathology, increased aggregation
and retention in Alzheimer’s disease could explain the de-
crease in CSF insulin levels despite increased blood–brain
barrier permeability in the disease.
A previous report has shown signs of alterations in IRS1
serine phosphorylation, which is a marker for insulin re-
sistance, in different tauopathies, including Alzheimer’s dis-
ease, CBD and PSP (Yarchoan et al., 2014). This effect was
neuron-speciﬁc and was not found in other neurodegenera-
tive disorders with no tau pathology, such as alpha synu-
cleopathies or TDP-43 proteinopathies (Yarchoan et al.,
2014). We found insulin accumulation together with hyper-
phosphorylated tau in CA1–CA3 hippocampal neurons in
CBD, PSP and AGD, which further suggests the existence
of a very close relationship between both pathological out-
comes. To further study this possibility, we used P301S
mice (Yoshiyama et al., 2007) and we found insulin accu-
mulation in the hippocampus occurring in parallel to tau
pathology. Similarly, accumulation of insulin was found in
stable tau-overexpressing SH-SY5Y cells. Furthermore, in a
cellular model of tau hyperphosphorylation, where rat cor-
tical neurons were treated with the phosphatases inhibitor
okadaic acid, we found that tau hyperphosphorylation was
accompanied by insulin accumulation in the neurons.
However, if okadaic acid was used under tau silencing con-
ditions, the accumulation of insulin was not found, suggest-
ing that tau pathology triggers insulin accumulation and
oligomerization. In agreement with the results observed
in Alzheimer’s disease brains, okadaic acid treatment led
to the development of intracellular tau ﬁbres and insulin
aggregates in neurons, identiﬁed as oligomeric by immuno-
precipitation with the anti-pan-oligomers antibody A11.
As seen in Alzheimer’s disease brains, tau ﬁbres and insu-
lin oligomers did not co-localize in our cellular models.
Using alternative in vitro models, we found that overex-
pression of total tau, or pseudo-phosphorylated tau
resulted in a signiﬁcant increase of intracellular insulin
compared to both wild-type and overexpressing phospho-
null tau cells. Together, our results suggest that tau hyper-
phosphorylation, rather that tau enhancement, drives
insulin accumulation inside the cells.
IDE is the main enzyme responsible for insulin degrad-
ation (Farris et al., 2003), and has been found to be
decreased in the hippocampus of APOE4 carriers compared
to non-APOE4 carriers in Alzheimer’s disease (Cook et al.,
2003). However, others showed that IDE levels are un-
changed in Alzheimer’s disease brains compared to controls
(Miners et al., 2009). We found that okadaic acid treat-
ment does not change IDE protein levels in primary neu-
rons, suggesting that okadaic acid-induced intraneuronal
insulin accumulation was not due to deﬁciencies in its deg-
radation. As neurons in primary culture and hippocampal
neurons in the brain have been reported to synthesize in-
sulin (Steen et al., 2005; Molna´r et al., 2014), we next
interrogated if insulin accumulation was caused by
increased insulin uptake or by increased synthesis.
Incubation with FITC labelled human recombinant insulin
in okadaic acid-treated neurons for 1 h revealed increased
insulin uptake in these cells. Quantitative PCR analysis of
insulin expression levels showed no differences in insulin
synthesis, suggesting that the increased insulin levels
observed in okadaic acid-treated neurons result from accu-
mulation of extracellular insulin.
It is well known that insulin signalling alterations
contribute to hyperphosphorylation and accumulation of
tau (Avila, 2008; Liu et al., 2009); on the other hand,
the effect of tau alterations on insulin signalling is not suf-
ﬁciently understood. We show that both tau-overexpressing
SH-SY5Y cells and okadaic acid-treated neurons have
decreased insulin receptor levels. Tau-overexpressing
SH-SY5Y cells also showed a signiﬁcant decrease in AKT
phosphorylation and GLUT4 expression levels, which add-
itionally support the concept that these cells have basal
deﬁciencies in insulin signalling. Moreover, in okadaic
acid-treated neurons, removing insulin from the media pre-
vented the decrease in insulin receptor levels. This evidence
suggests that cells suffering from tau hyperphosphorylation
show enhanced insulin uptake, which in the long-term leads
to insulin resistance.
In summary, our results demonstrate that tau hyperpho-
sphorylation leads to increased uptake and accumulation of
insulin as insoluble oligomeric aggregates inside neurons.
Cells with accumulated insulin show decreased insulin re-
ceptor levels and signs of insulin resistance. Previous reports
demonstrated the existence of insulin receptor downregula-
tion, neuronal resistance to insulin and glucose hypometa-
bolism in Alzheimer’s disease and other tauopathies (Steen
et al., 2005; Molna´r et al., 2014), but the mechanisms
Figure 4 Continued
or absence (Ins) of insulin in the media. Bars show mean values  SEM of three independent experiments. **P5 0.01 versus control, *P5 0.05
versus control, #P5 0.05 versus its control (Ins control).
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remain to be fully understood. Our present study provides
novel evidence suggesting accumulation of intraneuronal oli-
gomeric insulin as a contributing factor to the insulin resist-
ance reported in these diseases. Likewise, insulin
accumulation could have functional consequences for insu-
lin recycling, homeostasis and glucose metabolism in brain
and contribute to these neurodegenerative processes. The
results presented also suggest that the therapeutic use of
insulin for the treatment of neurodegenerative disorders
with associated tauopathy should be used with caution.
Acknowledgements
We would like to acknowledge Hans Blom, from the
Superresolution Microscopy Science for Life Laboratory
for his assistance and advice with the superresolution
images and the Harvard Brain Tissue Resource Center for
providing brain samples for protein determinations. We ac-
knowledge Tomas Ho¨kfelt for the supply of insulin anti-
body Ab909. This study was performed at the Live Cell
Imaging facility, Karolinska Institutet, Sweden, supported
by grants from the Knut and Alice Wallenberg
Foundation, the Swedish Research Council, the Centre for
Innovative Medicine and the Jonasson center at the Royal
Institute of Technology, Sweden.
Funding
The Harvard Brain Tissue Resource Center is supported in
part by PHS grant number R24MHO68855 for providing
brain samples for protein determinations. P.M.S. was the
recipient of the EMBO long-term fellowship (ALFT 696-
2013) and the SSMF postdoctoral fellowship. This research
was supported by the following Swedish foundations:
Swedish Brain Power, the regional agreement on medical
training and clinical research (ALF) between Stockholm
County Council and Karolinska Institutet, Margaretha af
Ugglas Foundation, Olle Engkvist Byggma¨stare Stiftelse,
Gun och Bertil Stohnes Stiftelse, Loo och Hans Osterman
Foundation, Karolinska Institutet fund for geriatric re-
search, Stiftelsen Gamla Tja¨narinnor, Riskbankens
Jubileumfonden, Hja¨rnfonden and Alzheimerfonden.
Supplementary material
Supplementary material is available at Brain online.
References
Applied Biosystems. Guide to performing relative quantitation of gene
expression using real-time quantitative PCR. Foster City: Applied
Biosystems; 2004.
Avila J. Tau kinases and phosphatases. J Cell Mol Med 2008; 12:
258–9.
Bian H, Bian W, Lin X, Ma Z, Chen W, Pu Y. RNA Interference
silencing of glycogen synthase kinase 3beta inhibites tau phosphor-
ylation in mice with Alzheimer disease. Neurochem Res 2016; 41:
2470–80.
Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s
disease. Acta Neurol Scand Suppl 1996; 165: 3–12.
Broetto N, Hansen F, Brolese G, Batassini C, Lirio F, Galland F, et al.
Intracerebroventricular administration of okadaic acid induces hip-
pocampal glucose uptake dysfunction and tau phosphorylation.
Brain Res Bull 2016; 124: 136–43.
Calvo-Ochoa E, Herna´ndez-Ortega K, Ferrera P, Morimoto S, Arias
C. Short-term high-fat-and-fructose feeding produces insulin signal-
ing alterations accompanied by neurite and synaptic reduction and
astroglial activation in the rat hippocampus. J Cereb Blood Flow
Metab 2014; 34: 1001–8.
Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates
synapse number, dendritic plasticity, and circuit function in vivo.
Neuron 2008; 58: 708–19.
Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth
RA, et al. Reduced hippocampal insulin-degrading enzyme in late-
onset Alzheimer’s disease is associated with the apolipoprotein E-
epsilon4 allele. Am J Pathol 2003; 162: 313–19.
Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP.
Inhibition of neuronal maturation in primary hippocampal neurons
from tau deﬁcient mice. J Cell Sci 2001; 114: 1179–87.
de la Monte SM, Re E, Longato L, Tong M. Dysfunctional pro-cer-
amide, ER stress, and insulin/IGF signaling networks with progres-
sion of Alzheimer’s disease. J Alzheimers Dis 2012; 30: S217–29
de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-
evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101–13.
Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK,
Zahm DS. Insulin gene expression and insulin synthesis in mamma-
lian neuronal cells. J Biol Chem 1994; 269: 8445–54.
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch
MP, et al. Insulin-degrading enzyme regulates the levels of insulin,
amyloid beta-protein, and the beta-amyloid precursor protein intra-
cellular domain in vivo. Proc Natl Acad Sci USA 2003; 100:
4162–7.
Ferrer I, Santpere G, Van Leeuwen FW. Argyrophilic grain disease.
Brain 2008; 131: 1416–32.
Garcı´a-Ca´ceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B,
et al. Astrocytic insulin signaling couples brain glucose uptake with
nutrient availability. Cell 2016; 166: 867–80.
Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M,
et al. Insulin levels are decreased in the cerebrospinal ﬂuid of women
with prodomal Alzheimer’s disease. J Alzheimers Dis 2010; 22:
405–13.
Gustafsson MG. Surpassing the lateral resolution limit by a factor of
two using structured illumination microscopy. J Microsc 2000; 198:
82–7.
Hjorth CF, Norrman M, Wahlund PO, Benie AJ, Petersen BO, Jessen
CM, et al. Structure, Aggregation, and activity of a covalent insulin
dimer formed during storage of neutral formulation of human insu-
lin. J Pharm Sci 2016; 105: 1376–86.
Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK,
et al. Tau mislocalization to dendritic spines mediates synaptic dys-
function independently of neurodegeneration. Neuron 2010; 68:
1067–81.
Kapogiannis D, Boxer A, Schwartz JB, Abner EL, Biragyn A,
Masharani U, et al. Dysfunctionally phosphorylated type 1 insulin
receptor substrate in neural-derived blood exosomes of preclinical
Alzheimer’s disease. FASEB J 2015; 29: 589–96.
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman
CW, et al. Common structure of soluble amyloid oligomers implies
common mechanism of pathogenesis. Science 2003; 300: 486–9.
Kennedy L, Pham SC, Grishok A. Nonautonomous regulation of neur-
onal migration by insulin signaling, DAF-16/FOXO, and PAK-1.
Cell Rep 2013; 4: 996–1009.
16 | BRAIN 2017: Page 16 of 17 P. Rodriguez-Rodriguez et al.
Kim B, Figueroa-Romero C, Pacut C, Backus C, Feldman EL. Insulin
resistance prevents AMPK-induced tau dephosphorylation through
akt-mediated increase in AMPKSer-485 phosphorylation. J Biol Chem
2015; 290: 19146–57.
Komis G, Sˇamajova´ O, Ovecˇka M, Sˇamaj J. Super-resolution micro-
scopy in plant cell imaging. Trends Plant Sci 2015; 20: 834–43.
Lee S, Tong M, Hang S, Deochand C, de la Monte S. CSF and brain
indices of insulin resistance, oxidative stress and neuro-inﬂammation
in early versus late Alzheimer’s disease. J Alzheimers Dis Park 2013;
3: 128.
Lin JW, Ju W, Foster K, Lee SH, Ahmadian G, Wyszynski M, et al.
Distinct molecular mechanisms and divergent endocytotic pathways
of AMPA receptor internalization. Nat Neurosci 2000; 3: 1282–90.
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-
GlcNAcylation regulates phosphorylation of tau: a mechanism
involved in Alzheimer’s disease. Proc Natl Acad Sci USA 2004;
101: 10804–9.
Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, et al. Reduced
O-GlcNAcylation links lower brain glucose metabolism and tau
pathology in Alzheimer’s disease. Brain 2009; 132: 1820–32.
Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, et al.
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer
neuroﬁbrillary pathology. In Focus. J Cell Mol Med 2008; 12:
241–57.
Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and
risk of Alzheimer disease. Neurology 2004; 63: 1187–92.
Mangla A, Kim GJ, Agarwal N, Khurana S, Catchatourian R, Jiang JJ.
Localized insulin amyloidosis with use of concentrated insulin: a
potential complication. Diabet Med 2016; 33: e32–5.
Miners JS, Baig S, Tayler H, Kehoe PG, Love S. Neprilysin and insu-
lin-degrading enzyme levels are increased in Alzheimer disease in
relation to disease severity. J Neuropathol Exp Neurol 2009; 68:
902–14.
Molna´r G, Farago´ N, Kocsis A´K, Ro´zsa M, Lovas S, Boldog E, et al.
GABAergic neurogliaform cells represent local sources of insulin in
the cerebral cortex. J Neurosci 2014; 34: 1133–7.
Monroy-Ramı´rez HC, Basurto-Islas G, Mena R, Cisneros B, Binder LI,
Avila J, et al. Alterations in the nuclear architecture produced by the
overexpression of tau protein in neuroblastoma cells. J Alzheimers
Dis 2013; 36: 503–20.
Mullins RJ, Mustapic M, Goetz EJ, Kapogiannis D. Exosomal bio-
markers of brain insulin resistance associated with regional atrophy
in Alzheimer’s disease. Hum Brain Mapp 2017; 38: 1933–40.
Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R.
Insulin has multiple antiamyloidogenic effects on human neuronal
cells. Endocrinology 2013; 154: 375–87.
Pe´rez M, Herna´ndez F, Go´mez-Ramos A, Smith M, Perry G, Avila J.
Formation of aberrant phosphotau ﬁbrillar polymers in neural cul-
tured cells. Eur J Biochem 2002; 269: 1484–9.
Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K.
Permeability of proteins at the blood-brain barrier in the normal
adult mouse and double transgenic mouse model of Alzheimer’s
disease. Neurobiol Dis 2001; 8: 555–67.
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte
SM. Insulin and insulin-like growth factor expression and function
deteriorate with progression of Alzheimer’s disease: link to brain
reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247–68.
Sandebring A, Welander H, Winblad B, Graff C, Tjernberg LO. The
pathogenic abeta43 is enriched in familial and sporadic Alzheimer
disease. PLoS One 2013; 8: e55847.
Schermelleh L, Heintzmann R, Leonhardt H. A guide to super-reso-
lution ﬂuorescence microscopy. J Cell Biol 2010; 190: 165–75.
Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al.
Role for neuronal insulin resistance in neurodegenerative diseases.
Proc Natl Acad Sci USA 2004; 101: 3100–5.
Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin pro-
motes rapid delivery of N-methyl-D- aspartate receptors to the cell
surface by exocytosis. Proc Natl Acad Sci USA 2001; 98: 3561–6.
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al.
Impaired insulin and insulin-like growth factor expression and sig-
naling mechanisms in Alzheimer’s disease–is this type 3 diabetes?
J Alzheimers Dis 2005; 7: 63–80.
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al.
Demonstrated brain insulin resistance in Alzheimer’s disease patients
is associated with IGF-1 resistance, IRS-1 dysregulation, and cogni-
tive decline. J Clin Invest 2012; 122: 1316–38.
Upadhaya AR, Lungrin I, Yamaguchi H, Fa¨ndrich M, Thal DR. High-
molecular weight Ab oligomers and protoﬁbrils are the predominant
Ab species in the native soluble protein fraction of the AD brain.
J Cell Mol Med 2012; 16: 287–95.
van de Haar HJ, Burgmans S, Jansen JF, van Osch MJ, van Buchem
MA, Muller M, et al. Blood-brain barrier leakage in patients with
early Alzheimer disease. Radiology 2016; 281: 527–35.
Wegel E, Go¨hler A, Lagerholm BC, Wainman A, Uphoff S, Kaufmann
R, et al. Imaging cellular structures in super-resolution with SIM,
STED and localisation microscopy: a practical comparison. Sci Rep
2016; 6: 27290.
Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian
BT, et al. Association of insulin resistance with cerebral glucose
uptake in late middle–aged adults at risk for Alzheimer disease.
JAMA Neurol 2015a; 72: 1013.
Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker
LD, et al. Insulin resistance predicts brain amyloid deposition in late
middle-aged adults. Alzheimers Dement 2015b; 11: 504–10.
Williamson DF, Parker RA, Kendrick JS. The box plot: a sim-
ple visual method to interpret data. Ann Intern Med 1989; 110:
916–21.
Xie C, Miyasaka T. The role of the carboxyl-terminal sequence of tau
and MAP2 in the pathogenesis of dementia. Front Mol Neurosci
2016; 9: 158.
Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes melli-
tus and risk of dementia in the Kungsholmen project: a 6-year
follow-up study. Neurology 2004; 63: 1181–6.
Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, Han LY,
et al. Abnormal serine phosphorylation of insulin receptor substrate
1 is associated with tau pathology in Alzheimer’s disease and tauo-
pathies. Acta Neuropathol 2014; 128: 679–89.
Yoshida M. Cellular tau pathology and immunohistochemical study of
tau isoforms in sporadic tauopathies. Neuropathology 2006; 26:
457–70.
Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A.
Amyloid oligomer conformation in a group of natively folded pro-
teins. PLoS One 2008; 3: e3235.
Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC,
et al. Synapse loss and microglial activation precede tangles in a
P301S tauopathy mouse model. Neuron 2007; 53: 337–51.
Yuzwa SA, Vocadlo DJ. O-GlcNAc and neurodegeneration: biochem-
ical mechanisms and potential roles in Alzheimer’s disease and
beyond. Chem Soc Rev 2014; 43: 6839–58.
Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ,
et al. Insulin-degrading enzyme as a downstream target of insulin
receptor signaling cascade: implications for Alzheimer’s disease
intervention. J Neurosci 2004; 24: 11120–6.
Zhao W, Wu X, Xie H, Ke Y, Yung WH. Permissive role of insulin in
the expression of long-term potentiation in the hippocampus of im-
mature rats. Neurosignals 2011; 18: 236–45.
Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA,
et al. Insulin receptor dysfunction impairs cellular clear-
ance of neurotoxic oligomeric Ab. J Biol Chem 2009; 284:
18742–53.
Tau and insulin accumulation in neurons BRAIN 2017: Page 17 of 17 | 17
